Search clinical trials for: PG13-CEA_TCR (Anti-CEA TCR PBL)

Total 34 results

National Cancer Institute (NCI)

Terminated

Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

Metastatic Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Terminated

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Kidney Cancer | Renal Cancer

United States
National Cancer Institute (NCI)

Terminated

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
National Cancer Institute (NCI)

Completed

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Melanoma | Skin Cancer

United States
National Cancer Institute (NCI)

Terminated

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
National Cancer Institute (NCI)

Withdrawn

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
National Cancer Institute (NCI)

Withdrawn

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)

No longer available

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Cancer Institute (NCI)

Recruiting

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Gastric Cancer | Pancreatic Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Gastric Cancer | Pancreatic Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Melanoma | Cervical Cancer | Breast Cancer | Renal Cancer | Urothelial Cancer

United States
National Cancer Institute (NCI)

Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Breast Cancer | Multiple Myeloma | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Gastrointestinal/Genitourinary Cancers | Endocrine Tumors

United States
Chang Gung Memorial Hospital

Terminated

Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation

Flexible Bronchoscopy

Taiwan
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
University of Sao Paulo General Hospital

Completed

MPA Pharmacokinetics in Renal Transplantation

Kidney Transplantation Recipients

Brazil
National Cancer Institute (NCI)

Terminated

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Skin Cancer | Metastatic Melanoma

United States
Jonsson Comprehensive Cancer Center

Active, not recruiting

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Malignant Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Daiichi Sankyo, Inc.

Completed

Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children

Otitis Media
University of California, San Francisco
Kenya Medical Research Institute

Completed

Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women (SAVE)

Cervical Cancer | Cervical Intraepithelial Neoplasia | HIV

Kenya
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients (Imperial)

Pulmonary Disease, Chronic Obstructive

United Kingdom
Swiss Tropical & Public Health Institute
Institute of Tropical Medicine, Belgium; B.P. Koirala Institute of Health Sciences and other collaborators

Completed

Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (NIDIAGDigest)

Shigellosis | Schistosomiasis | Strongyloidiasis | Dientamoebiasis | Giardiasis | Amoebiasis | Soil-transmitted Helminthiasis | Intestinal Salmonellosis | Campylobacteriosis | Aeromonas Spp. Infections | Cryptosporidium Spp. Infections

Côte D'Ivoire, Indonesia, Mali, Nepal
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
Liaoning University of Traditional Chinese Medicine
Ministry of Science and Technology of the People´s Republic of China

Completed

Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index

Coronary Heart Disease | Stable Angina Pectoris

China
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells Present

United States
Agendia
University of South Florida; University of Miami; University of Oklahoma; Ohio... and other collaborators

Completed

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT)

Breast Cancer

United States
Shandong Cancer Hospital and Institute

Unknown

Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction (BCSMANC)

Breast Cancer

China
Clinical Research Support Center Kyush

Unknown

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

Rectal Cancer

Japan
Freeman-Sheldon Research Group, Inc.

Terminated

Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions (FSS-QLS)

Depressive Disorder | Craniofacial Abnormalities | Posttraumatic Stress Disorder | Arthrogryposis

United States, Guatemala
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States

Search clinical trials for: PG13-CEA_TCR (Anti-CEA TCR PBL)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations